Mylan launches generic Faslodex

Mylan is introducing its generic Faslodex injection  (fulvestrant injection). The generic of AstraZeneca's product will be available in a dosage strength of 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe.

It is used to treat certain types of advanced breast cancer in women who have experienced menopause as monotherapy and in advanced or metastatic breast cancer in combination with other products.

"Mylan's launch of fulvestrant injection represents an important addition to our growing oncology portfolio and, more importantly, expands the available treatment options for women who are facing advanced or metastatic stages of breast cancer," said Mylan president Rajiv Malik. "The launch also reinforces our scientific expertise in bringing to market complex products, like injectables, which further enhances our institutional business and exemplifies our continued commitment to expanding access to medicine."

Fulvestrant injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, had a market value of approximately $550 million for the 12 months ended June 30, according to IQVIA.